The design of vaccines against Helicobacter pylori and their development

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 523-563

  Del Giudice, G ^a   Covacci, A ^a   Telford, J L ^a   Montecucco, C ^a   Rappuoli, R ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Adjuvants; Animal models; Helicobacter pylori; Mucosal immunity; Vaccines

Indexed keywords

CYTOTOXIN; HELICOBACTER PYLORI VACCINE; INTERLEUKIN 8; UREASE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GRAM NEGATIVE INFECTION; HUMAN; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CATS; CLINICAL TRIALS, PHASE I; DOGS; DRUG THERAPY, COMBINATION; FERRETS; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MACACA MULATTA; MICE; MODELS, ANIMAL; SPECIES SPECIFICITY; SWINE; TH1 CELLS; UREASE; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035062020     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.523     Document Type: Review

References (240)

1. Über die schlauchförmingen drüsen des magendarmkanals und die beziehungen ihres epithels zu dem oberflächenepithel der schleimhaut
2. Unidentified curved bacilli on gastric epithelium in active chronic gastritis
3. Unidentified curved bacilli on gastric epithelium in active chronic gastritis
4. Helicobacter pylori: Pathogenic determinants and strategies for vaccine design
5. Natural gastric infection with Helicobacter pylori in monkeys
6. The epidemiology of Helicobacter pylori
7. Helicobacter pylori colonization in early life
8. When is Helicobacter pylori infection acquired?
9. Increasing prevalence of Helicobacter pylori infection with age - Continuous risk of infection in adults rather than cohort effect
10. The epidemiology and transmission of Helicobacter pylori in children
11. Helicobacter pylori among preschool children and their parents: Evidence of parent-child transmission
12. Acquisition of Helicobacter pylori infection in a high-risk population occurs within the first 2 years of life
13. Evidence from a nine-year birth cohort study in Japan of transmission pathways of Helicobacter pylori infection
14. DNA fingerprinting of single colonies of Helicobacter pylori from gastric cancer patients suggests infection with a single predominant strain
15. Pets are not a risk factor for Helicobacter pylori infection in young children: Results of a population-based study in Southern Germany
16. Helicobacter priori in the drinking water in Peru
17. Helicobacter pylori in sheep milk
18. Fecal and oral shedding of Helicobacter pylori from healthy infected adults
19. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission
20. Helicobacter pylori: The size of the problem
21. Antibiotic treatment of Helicobacter pylori infection
22. Experience with "triple" anti-Helicobacter eradication therapy: Side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance
23. Antibiotic resistance in Helicobacter pylori: Implications for therapy
24. Duodenal ulcer treatment with Helicobacter pylori eradication: Seven year follow-up
25. Low rates of Helicobacter pylori reinfection in children
26. Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication
27. Helicobacter pylori infection, gastric acid secretion, and infant growth
28. The complete genome sequence of the gastric pathogen Helicobacter pylori
29. Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
30. Comparative genomics of Helicobacter pylori: Analysis of the outer membrane protein families
31. Helicobacter pylori, virulence and genetic geography
32. Synthesis and activity of Helicobacter pylori urease and catalase at low pH
33. Molecular biology of ureases
34. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic pigs
35. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori
36. The metabolism and enzymes of Helicobacter pylori: Function and potential virulence effects
37. Mechanisms of Helicobacter pylori infection: Bacterial factors
38. Surface localization of Helicobacter pylori urease and heat shock protein homolog requires bacterial autolysis
39. Localization of Helicobacterpylori urease and heat shock protein in human gastric biopsies
40. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico
41. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease
42. Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer
43. Cytotoxin activity in broth-culture filtrates of Campylobacter pylori
44. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains
45. Purification and characterization of the vacuolating toxin from Helicobacter pylori
46. Identification of the Helicobacter pylori VacA toxin domain in the cell cytosol
47. Identification of the minimal intracellular domain of the Helicobacter pylori vacuolating toxin
48. 3D structure and location in the holotoxin holigomer of the 58 kDa cell binding subunit of the Helicobacter pylori cytotoxin
49. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin
50. Acid-induced dissociation of VacA, the Helicobacter pylori vacuolating cytotoxin, reveals its pattern of assembly
51. Low pH activates the vacuolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant
52. Vacuoles induced by Helicobacterpylori toxin contain both late endosomal and lysosomal markers
53. Binding of Helicobacter pylori cytotoxin to target cells
54. Morphologic differentiation of HL-60 cells is associated with appearance of RPTPβ and induction of Helicobacter pylori VacA sensitivity
55. The small GTP binding protein rab7 is essential for cellular vacuolation induced by Helicobacter priori cytotoxin
56. Selective inhibition of Ii-dependent antigen presentation by Helicobacter priori toxin VacA
57. Persistent infection by Helicobacter pylori down-modulates virus-specific CDS+ cytotoxic T cell response and prolongs viral infection
58. Effect of Helicobacter priori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation
59. Helicobacter priori vacuolating toxin increases the permeability of polarized epithelial cells monolayers
60. Helicobacter pylori VacA cytotoxin associated to bacteria increases epithelial permeability independently of its vacuolating activity
61. Enterotoxic effect of the vacuolating toxin produced by Helicobacter priori in Caco-2 cells
62. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition
63. Detection of a vacuolating cytotoxin in stools from children with diarrhea
64. Towards deciphering the Helicobacter priori cytotoxin
65. Cell specificity of Helicobacter priori cytotoxin is determined by a short region in the polymorphic midregion
66. Vacuolating toxin production in clinical isolates of Helicobacter priori with different vacA genotypes
67. Failure to confirm association of vacA gene mosiacism with duodenal ulcer disease
68. The m2 form of Helicobacter priori cytotoxin has cell type-specific vacuolating activity
69. Detection of anti-VacA antibody responses in serum and gastric juice samples using type s1/m1 and s2/m2 Helicobacter priori VacA antigens
70. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter priori associated with cytotoxicity and duodenal ulcer
71. Cloning and expession of a high-molecular-mass major antigen of Helicobacter pylori: Evidence of linkage to cytotoxin production
72. Analysis and expression of VacA and CagA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin
73. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity
74. Detection in an enzyme immunoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori
75. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori strains
76. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori and serum pepsinogens: An international study, the Eurogast Study Group
77. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors
78. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases
79. Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology
80. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan
81. Infection with Helicobacter pylori expressing the cagA gene is not associated with an increased risk of developing peptic ulcer diseases in Korean patients
82. Induction of host signal transduction pathways by Helicobacter pylori
83. Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the protooncogenes c-fos and c-jun
84. Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-B activation
85. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori
86. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells
87. Tyrosine phosphorylation of Helicobacter pylori CagA antigen after cag-driven host cell translocation
88. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion
89. Translocation of the Helicobacter CagA protein in gastric epithelial cells by a type IV secretion apparatus
90. Tyrosinephosphorylated bacterial proteins: Trojan horses for the host cell
91. Serology detection of infection with cagA+ Helicobacter pylori strains
92. Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies
93. Antrum and corpus mucosa-infiltrating CD4+ lymphocytes in Helicobacter priori gastritis display a Th1 phenotype
94. Local cytokine response in Helicobacter priori infected subjects
95. Lymphocytes in the human gastric mucosa during Helicobacter priori infection have a T helper cell 1 phenotype
96. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice
97. Immunization of BALB/cmice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection
98. A predominant Th1 type of immune response is induced early during acute Helicobacter pylori infection in rhesus macaques
99. Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication
100. Relationship between infective load of Helicobacter priori and reactive oxygen metabolite production in antral mucosa
101. Epithelial cytotoxicity, immune responses, and inflammatory components of Helicobacter priori gastritis
102. Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication
103. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism
104. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa
105. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils
106. Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leukocytes and monocytes
107. Activation of human phagocyte oxidative metabolism by Helicobacter pylori
108. Mechanisms involved in Helicobacter pylori-induced inflammation
109. Characterization of a Helicobacter pylori neutrophil-activating protein
110. Identification of four new prokaryotic bacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis and Treponema pallidum, by analysis of gene sequences
111. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure
112. The crystal structure of Dps, a ferritin homolog that binds and protects DNA
113. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor
114. Suitability of the neutrophil activating protein (HP-NAP) as a vaccine candidate
115. Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies
116. Attempt to fulfil Koch's postulates for pyloric Campylobacter
117. Ingestion of Campylobacter pyloridis causes gastritis and raised resting gastric pH
118. Acute Helicobacter pylori infection: Clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations
119. Acute Helicobacter pylori infection in an infant, associated with gastric ulceration and serological evidence of intrafamilial transmission
120. H. pylori vaccine development in humans: Challenge model
121. A small animal model of human Helicobacter pylori active chronic gastritis
122. Cloning, expression, and sequencing of Helicobacter felis urease genes
123. The Hsp60 of Helicobacter pylori: Structure and immune response in patients with gastroduodenal diseases
124. Helicobacter pylori hspA-hspB heat-shock gene cluster: Nucleotide sequence, expression, putative function and immunogenicity
125. Development of a mouse model of Helicobacter pylori infection that mimics human disease
126. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease
127. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
128. In vivo selection of a highly adapted H. pylori isolate and the development of a H. pylori model for studying vaccine efficacy
129. A standardized mouse model of Helicobacter pylori infection
130. A rat model of chronic Helicobacter pylori infection. Studies of epithelial cell turnover and gastric ulcer healing
131. Experimental Helicobacter pylori infection induces antral gastritis and gastric mucosa-associated lymphoid tissue in guinea pigs
132. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori
133. Gastric ulcer, atrophic gastritis, and intestinal metaplasia caused by Helicobacter infection in Mongolian gerbils
134. Experimental infection of Mongolian gerbils with wild-type and mutants Helicobacter pylori strains
135. Helicobacter pylori induces gastric cancer in Mongolian gerbils
136. Adaptive mutation and cocolonization during Helicobacter pylori infection of gnotobiotic piglets
137. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes
138. The nonhuman primate model for H. pylori infection
139. Helicobacter mustelaeassociated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans
140. Identification of a cagA gene in Helicobacter mustelae strains
141. Characterization of feline Helicobacter pylori strains and associated gastritis in a colony of domestic cats
142. Helicobacter pylori-induced gastritis in the domestic cat
143. Helicobacter pylori gastritis in cats with long-term natural infection as a model of human disease
144. Failure to isolate Helicobacter pylori from stray cats indicate that H. pylori in cats may be an anthroponosis - An animal infection with a human pathogen
145. Helicobacter pylori gastric infection in gnotobiotic beagle dogs
146. A conventional beagle dog model for acute and chronic infection with Helicobacter pylori
147. Immunohistochemical study of the lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with Helicobacter pylori
148. Oral immunization against Helicobacter pylori
149. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
150. Immunisation against gastric Helicobacter infection in a mouse/Helicobacter felis model
151. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
152. Therapeutic immunization against Helicobacter infection
153. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies
154. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa
155. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity
156. Molecular mimicry between Helicobacter pylori and the host
157. A role for the bacterial outer membrane in the pathogenesis of Helicobacter pylori infection
158. Persistence of Helicobacter pylori VacA toxin and vacuolating potential in cultured gastric epithelial cells
159. Immune response to an 18-kilodalton outer membrane antigen lipoprotein 20 as a Helicobacter pylori vaccine candidate
160. Lack of protection following immunization with Helicobacter pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori
161. Isolation of recombinant protective Helicobacter pylori antigens
162. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine
163. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heatlabile enterotoxin with partial knockout of ADP-ribosyltransferase activity
164. Recombinant antigens prepared from the urease subunits of Helicobacter spp: Evidence of protection in a mouse model of gastric infection
165. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis
166. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection
167. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
168. Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection
169. Urease subunits A and B delivered by attenuated Salmonella typhimurium vaccine strain protects mice against gastric colonization by Helicobacter pylori
170. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits
171. Oral immunization with Helicobacter pylori urease B subunit as a treatment aainst Helicobacter infection in mice
172. Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice
173. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection
174. Urease-based mucosal immunization against Helicobacter heilmannii infection induces corpus atrophy in mice
175. Systemic immunization with urease protects mice against Helicobacter pylori infection
176. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
177. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets
178. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
179. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
180. Immunization against natural Helicobacter pylori infection in nonhuman primates
181. Mucosal, systemic, or combined therapeutic immunization in cynomolgus monkeys naturally infected with Gastrospirillum hominis-like organisms
182. Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta)
183. Rational design of vaccines
184. Detoxification of Helicobacter pylori cytotoxin
185. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice
186. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice
187. Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori
188. Catalase, a novel antigen for Helicobacter pylori vaccination
189. Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein
190. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis
191. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
192. Vaccination of gnotobiotic piglets against Helicobacter pylori
193. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis
194. Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice
195. Promotion of ulcerative duodenatis in young ferrets by oral immunization with Helicobacter mustelae and muramyl dipeptide
196. Serological methods for diagnosis of Helicobacter pylori infection and monitoring of eradication therapy
197. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori subjects
198. Characterization and therapy of experimental infection by Helicobacter mustelae in ferrets
199. Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets
200. Acquisition versus loss of Helicobacter pylori infection in Japan: Results from an 8-year birth cohort study
201. History of antibiotic treatment and prevalence of H. pylori infection among children: Results of a population-based study
202. Antigen sampling across epithelial barriers and induction of mucosal immune responses
203. Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed gastric mucosa
204. Expression of B7-1 and B7-2 costimulatory molecules by human gastric epithelial cells. Potential role of CD4+ T cell activation during Helicobacter pylori infection
205. Expression of HLA-DR, costimulatory molecules B7-1, B7-2, intercellular adhesion molecule-1 (ICAM-1) and Fas ligand (FasL) on gastric epithelial cells in Helicobacter pylori gastritis, Influence of H. pylori eradication
206. Characterization of lymphocytic infiltrates in Helicobacter pylori-associated gastritis
207. An increased number of follicles containing activated CD69+ helper T cells and proliferating CD71+ B cells are found in H. pylori-infected gastric mucosa
208. Gastric lymphoid follicles in Helicobacter pylori infection: Frequency, distribution, and response to triple therapy
209. Gastric cancer and lymphoma
210. Humoral and cellular immune recognition of Helicobacter pylori proteins are not concordant
211. T-cell, antibody, and cytokine responses to homologs of the 60-kilodalton heat shock protein in Helicobacter pylori infection
212. Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis
213. Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with Helicobacter pylori
214. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferonproducing T cells in the human gastric mucosa
215. Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10-/- mice
216. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-γ, gene-deficient mice
217. Chemokines in the gastric mucosa in Helicobacter pylori infection
218. Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression
219. Tumor necrosis factor alpha and interleukin 1β up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection
220. Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas ligand interactions
221. Opsonic activity of specific human IgG against Helicobacter pylori
222. Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori
223. Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice
224. Orally-immunized IgA deficient mice are protected against H. felis infection
225. Mucosal immunity to influenza without IgA: An IgA knockout mouse model
226. Helicobacter pylori infection in IgA deficiency: Lack of role for the secretory immune system
227. Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice
228. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene
229. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions
230. Failure of immunization against Helicobacter infection in IL-4 deficient mice: Evidence for a Th2 immune response as the bias for protective immunity
231. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
232. New carriers and adjuvants in the development of vacciners
233. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
234. Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection
235. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group
236. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein A Lyme disease vaccine study consortium
237. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
238. Safety and immunogenicity of a Helicobacter pylori vaccine in human volunteers
239. Experimental challenge studies in the development of vaccines for infectious diseases